Invesaro

Stocks Comparison

U S Physical Therapy vs GeneDx: revenue, profit, margins and growth compared

U S Physical Therapy brought in $781M of revenue in fiscal 2025, GeneDx $427.5M in fiscal 2025. Revenue changed by +16.3% at U S Physical Therapy and +40.0% at GeneDx on the year before, so GeneDx grew faster. U S Physical Therapy kept 5.1% of its revenue as net profit, GeneDx -4.9%. Free cash flow was $61M at U S Physical Therapy and $14.3M at GeneDx.

Side by side, latest fiscal year

USPHWGS
Fiscal year endedFY2025 (December 31, 2025)FY2025 (December 31, 2025)
Revenue$781M$427.5M
Revenue growth+16.3%+40.0%
Net income$39.6M-$21M
Net margin5.1%-4.9%
Free cash flow$61M$14.3M
Free cash flow margin7.8%3.3%
Earnings per share (diluted)$1.42-$0.73
Cash$35.6M$105M
Debt$162.5M$54.5M
Price to earnings59.8n/a
Market value$1.3B$2.6B
Dividend yield2.12%n/a
Rank by revenue in sector#163 of 523 · Health care#199 of 523 · Health care

Over the years

Revenue
USPH FY2018: $453.9MUSPH FY2019: $482MUSPH FY2020: $423MUSPH FY2021: $495MUSPH FY2022: $553.1MUSPH FY2023: $604.8MUSPH FY2024: $671.3MUSPH FY2025: $781MWGS FY2019: $196.2MWGS FY2020: $179.3MWGS FY2021: $212.2MWGS FY2022: $234.7MWGS FY2023: $202.6MWGS FY2024: $305.5MWGS FY2025: $427.5MFY18FY19FY20FY21FY22FY23FY24FY25
USPH $781MWGS $427.5M
Net income
USPH FY2018: $34.9MUSPH FY2019: $40MUSPH FY2020: $35.2MUSPH FY2021: $40.8MUSPH FY2022: $32.2MUSPH FY2023: $28.2MUSPH FY2024: $31.4MUSPH FY2025: $39.6MWGS FY2019: -$29.7MWGS FY2020: -$241.3MWGS FY2021: -$245.4MWGS FY2022: -$549MWGS FY2023: -$175.8MWGS FY2024: -$52.3MWGS FY2025: -$21MFY18FY19FY20FY21FY22FY23FY24FY25
USPH $39.6MWGS -$21M
Net margin
USPH FY2018: 7.7%USPH FY2019: 8.3%USPH FY2020: 8.3%USPH FY2021: 8.2%USPH FY2022: 5.8%USPH FY2023: 4.7%USPH FY2024: 4.7%USPH FY2025: 5.1%WGS FY2019: -15.1%WGS FY2020: -134.6%WGS FY2021: -115.6%WGS FY2022: -233.9%WGS FY2023: -86.8%WGS FY2024: -17.1%WGS FY2025: -4.9%FY18FY19FY20FY21FY22FY23FY24FY25
USPH 5.1%WGS -4.9%
Revenue growth
USPH FY2019: +6.2%USPH FY2020: -12.2%USPH FY2021: +17.0%USPH FY2022: +11.7%USPH FY2023: +9.3%USPH FY2024: +11.0%USPH FY2025: +16.3%WGS FY2020: -8.6%WGS FY2021: +18.3%WGS FY2022: +10.6%WGS FY2023: -13.7%WGS FY2024: +50.8%WGS FY2025: +40.0%FY19FY20FY21FY22FY23FY24FY25
USPH +16.3%WGS +40.0%
Free cash flow
USPH FY2018: $65.8MUSPH FY2019: $52.3MUSPH FY2020: $92.4MUSPH FY2021: $68.2MUSPH FY2022: $50.3MUSPH FY2023: $72.7MUSPH FY2024: $65.8MUSPH FY2025: $61MWGS FY2019: -$30.7MWGS FY2020: -$117.2MWGS FY2021: -$199.8MWGS FY2022: -$326.3MWGS FY2023: -$185.4MWGS FY2024: -$34MWGS FY2025: $14.3MFY18FY19FY20FY21FY22FY23FY24FY25
USPH $61MWGS $14.3M

Fiscal years as each company reports them; the two may end in different months.

Questions about U S Physical Therapy and GeneDx

Which is bigger by revenue, U S Physical Therapy or GeneDx?

U S Physical Therapy is bigger by revenue: $781M in fiscal 2025, against $427.5M for GeneDx in fiscal 2025.

Which keeps more of its revenue as profit, U S Physical Therapy or GeneDx?

U S Physical Therapy had a net margin of 5.1% in fiscal 2025; GeneDx had -4.9% in fiscal 2025.

Which grew revenue faster, U S Physical Therapy or GeneDx?

In their latest fiscal years revenue changed by +16.3% at U S Physical Therapy and +40.0% at GeneDx.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies